Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950753 · ClinicalTrials.gov registry record · Early Phase 1
Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?
A Early Phase 1 study of Hyperlactatemia, sponsored by University Medical Center of Southern Nevada.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02950753: Completed Early Phase 1 study of Hyperlactatemia, sponsored by University Medical Center of Southern Nevada.
NCT02950753 is a Early Phase 1 study of Hyperlactatemia that has completed, run by University Medical Center of Southern Nevada. The registered enrollment target is 30 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02950753, a Early Phase 1 study of Hyperlactatemia, has completed, sponsored by University Medical Center of Southern Nevada.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Lactated Ringer's (LR) solution bolus is commonly administered in the emergency department setting to seriously ill patients. It is also common to obtain blood samples to determine serum lactate levels to aid in the assessment of the patient's degree of illness. This study endeavors to determine if serum lactate levels are affected by LR fluid administration in healthy adult individuals as compared to those who receive Normal Saline (NS). Healthy adult volunteers will be used as subjects so that the illness of hospital patients does not confound the results.
Primary Outcome
Final mean lactate minus initial mean lactate
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG Lactated Ringer Solution
Study Locations (1)
Nevada
- University Medical Center of Southern Nevada - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-01-04 |
| Est. Completion | 2017-06-01 |
| Phase | Early Phase 1 |
What the finished NCT02950753 record still lists
NCT02950753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Hyperlactatemia appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT02950753 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT02950753 about?
NCT02950753 is a clinical study titled "Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?". Lactated Ringer's (LR) solution bolus is commonly administered in the emergency department setting to seriously ill patients. It is also common to obtain blood samples to determine serum lactate levels to aid in the assessment of the patient's degree of illness. This study endeavors to determine if ...
What is the current status of trial NCT02950753?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2017-01-04. Estimated completion is 2017-06-01.
What conditions does trial NCT02950753 study?
This clinical trial studies the following conditions: Hyperlactatemia.
What interventions are being tested in trial NCT02950753?
The interventions under investigation include: Normal Saline (DRUG), Lactated Ringer Solution (DRUG).
Who is sponsoring clinical trial NCT02950753?
This trial is sponsored by University Medical Center of Southern Nevada, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02950753 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02950753's enrollment target sits among peer trials
30 807th of 2000 higher than 1,075 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI